^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Lymphocytic Lymphoma
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Preferred regimens…Venetoclax + rituximab